AGL 24.40 Increased By ▲ 1.46 (6.36%)
AIRLINK 109.29 Decreased By ▼ -2.00 (-1.8%)
BOP 5.29 Increased By ▲ 0.04 (0.76%)
CNERGY 3.67 Decreased By ▼ -0.05 (-1.34%)
DCL 8.00 Increased By ▲ 0.01 (0.13%)
DFML 44.30 Increased By ▲ 4.03 (10.01%)
DGKC 88.80 Increased By ▲ 0.80 (0.91%)
FCCL 21.99 No Change ▼ 0.00 (0%)
FFBL 42.28 Increased By ▲ 0.08 (0.19%)
FFL 8.90 Increased By ▲ 0.35 (4.09%)
HUBC 151.70 Decreased By ▼ -1.59 (-1.04%)
HUMNL 10.35 Decreased By ▼ -0.10 (-0.96%)
KEL 4.45 Decreased By ▼ -0.05 (-1.11%)
KOSM 3.95 Increased By ▲ 0.10 (2.6%)
MLCF 36.60 Decreased By ▼ -0.20 (-0.54%)
NBP 49.16 Increased By ▲ 1.17 (2.44%)
OGDC 131.70 Decreased By ▼ -0.10 (-0.08%)
PAEL 26.31 Increased By ▲ 0.16 (0.61%)
PIBTL 6.07 Increased By ▲ 0.04 (0.66%)
PPL 115.45 Decreased By ▼ -0.05 (-0.04%)
PRL 22.67 Increased By ▲ 0.07 (0.31%)
PTC 12.50 Decreased By ▼ -0.08 (-0.64%)
SEARL 56.19 Increased By ▲ 0.50 (0.9%)
TELE 7.40 Increased By ▲ 0.20 (2.78%)
TOMCL 37.69 Increased By ▲ 0.69 (1.86%)
TPLP 8.34 Increased By ▲ 0.49 (6.24%)
TREET 15.33 Increased By ▲ 0.03 (0.2%)
TRG 59.96 Increased By ▲ 5.41 (9.92%)
UNITY 32.34 Increased By ▲ 0.48 (1.51%)
WTL 1.18 Increased By ▲ 0.01 (0.85%)
BR100 8,406 Increased By 61.8 (0.74%)
BR30 26,453 Increased By 106 (0.4%)
KSE100 79,397 Increased By 409.9 (0.52%)
KSE30 25,518 Increased By 153.1 (0.6%)
World

EU regulators team up with US and UK on pharmaceutical mergers

  • The COVID-19 pandemic and vaccine supply bottlenecks have spurred regulatory interest in the pharmaceutical industry which has seen a wave of consolidation in recent years.
  • The EU competition enforcer said greater scrutiny of pharmaceutical deals was needed to single out those that might lead to higher drug prices, lower innovation or anti-competitive conduct.
Published March 16, 2021

BRUSSELS: EU antitrust enforcers have teamed up with their US and British counterparts to share expertise on how to examine mergers in the pharmaceutical industry amid concerns such deals could push up prices or hold back innovation.

The COVID-19 pandemic and vaccine supply bottlenecks have spurred regulatory interest in the pharmaceutical industry which has seen a wave of consolidation in recent years.

The European Commission said the working group, which was launched on Tuesday, included the US Federal Trade Commission (FTC), the Canadian Competition Bureau, Britain's Competition and Markets Authority and the US Department of Justice.

The group would "take stock of the lessons learned in recent years and explore new ways to foster vibrant competition to the benefit of citizens", European Competition Commissioner Margrethe Vestager said in a statement.

The EU competition enforcer said greater scrutiny of pharmaceutical deals was needed to single out those that might lead to higher drug prices, lower innovation or anti-competitive conduct.

"Given the high volume of pharmaceutical mergers in recent years, amid skyrocketing drug prices and ongoing concerns about anti-competitive conduct in the industry, it is imperative that we rethink our approach toward pharmaceutical merger review," FTC Acting Chair Rebecca Slaughter said in a statement.

High and rising US prescription drug prices, even for older medicines like insulin and epinephrine, have been a focus of concern for both US political parties. Both former President Donald Trump, in his 2016 campaign, and President Joe Biden, in his 2020 campaign, pledged to reduce drug costs.

Comments

Comments are closed.